Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03509948
Recruitment Status : Completed
First Posted : April 27, 2018
Results First Posted : September 12, 2019
Last Update Posted : September 24, 2019
Sponsor:
Information provided by (Responsible Party):
Achieve Life Sciences

Brief Summary:
This will be an open-label, randomised, 2-treatment period, single-dose crossover study to determine the comparative bioavailability and renal elimination following single-dose administration of 3.0 mg cytisine in healthy smokers under fed and fasted conditions.

Condition or disease Intervention/treatment Phase
Smoking Cessation Drug: cytisine Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open Label, Randomized, Two-Way Crossover Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation
Actual Study Start Date : April 27, 2018
Actual Primary Completion Date : June 10, 2018
Actual Study Completion Date : June 12, 2018

Arm Intervention/treatment
Experimental: Schedule A: Fed Then Fasted

Schedule A (6 participants):

  • Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)
  • Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)
Drug: cytisine
cytisine 1.5 mg film-coated tablets
Other Name: Tabex

Experimental: Schedule B: Fasted Then Fed

Schedule B (6 participants):

  • Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)
  • Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)
Drug: cytisine
cytisine 1.5 mg film-coated tablets
Other Name: Tabex




Primary Outcome Measures :
  1. Maximum Concentration (Cmax) [ Time Frame: Pre-dose (within 60 minutes prior to dosing), up to 48 hours post-dose on Days 1-5 ]
  2. Area Under the Concentration Versus Time Curve (AUC) Extrapolated to Infinity (AUC0-∞) [ Time Frame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5 ]
  3. Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h) [ Time Frame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5 ]
  4. Percent of Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h%) [ Time Frame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5 ]

Secondary Outcome Measures :
  1. Time to Cmax (Tmax) [ Time Frame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5 ]
  2. Terminal Elimination Half-Life (T1/2) [ Time Frame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5 ]
  3. AUC From Time of Dosing to Last Measurable Concentration (AUC0-t) [ Time Frame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5 ]
  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Withdrawal of Study Drug [ Time Frame: Baseline (Day 0) through Day 5 plus 6-8 days ]
    An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) is defined as an AE that: results in death; is life-threatening; requires hospitalization or prolongs existing inpatient hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes. TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of investigational product that worsen after the participant receives the first dose of investigational product. Relationship of the TEAE to study drug was evaluated as: definite, probably, possible, unlikely, or not related.

  5. Number of Participants With Clinically Significant Biochemistry, Hematology, Urinalysis, and/or 12-lead Electrocardiogram (ECG) Values [ Time Frame: Screening through Day 5 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be Confirmed at Screening

  1. Subject is current cigarette smoker.
  2. Healthy males and females between 18 and 55 years of age.

    1. If a female subject of child bearing potential, a negative pregnancy test at screening and admission and willing to use an effective method of contraception (unless of non-childbearing potential or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.
    2. If a female subject of non-child bearing potential, a negative pregnancy test at screening and admission. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at Investigator's discretion following consultation with the Sponsor.
    3. If a male subject, willing to use an effective method of contraception (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.
  3. Subject with a body mass index (BMI) of 23-28 kg/m^2. BMI = body weight in kg / [height in m^2].
  4. Subject with no clinically significant abnormal serum biochemistry or haematology values within 28 days before the first dose of cytisine.
  5. Subject with negative urinary drugs of abuse screen, determined within 28 days before the first dose of cytisine (a positive result may be repeated at Investigator's discretion).
  6. Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results.
  7. Subject with no clinically significant abnormalities in 12-lead ECG determined after minimum of 5 minutes in supine position within 28 days before the first dose of cytisine.
  8. Subject with no clinically significant abnormalities in vital signs (systolic blood pressure between 90-140 mmHg, diastolic blood pressure (DBP) between 50 and 90 mmHg, and pulse rate (PR) between 40-100 bpm, measured on the dominant arm after minimum of 5 minutes in supine position) determined within 28 days before first dose of cytisine.
  9. Subject must be available to complete the study (including post study follow-up) and comply with study restrictions.
  10. Subject must provide written informed consent to participate in the study.

To be Re-Confirmed Prior to Dosing

  1. Subject continues to meet all screening inclusion criteria (before the cytisine dose).
  2. Subject has a negative urinary drugs of abuse screen (including alcohol).
  3. Female subject has a negative urine pregnancy test.

Exclusion Criteria:

To be Confirmed at Screening

  1. Known hypersensitivity/allergy reaction to varenicline, other cytisine-derivatives or any of the excipients in the Tabex formulation (cellulose, talc, magnesium).
  2. History of severe hypersensitivity reactions to any other drugs.
  3. History of any medical condition (e.g. gastrointestinal, renal or hepatic) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion).
  4. Female subjects who are breast feeding.
  5. Difficulty in donating blood on either arm or known history.
  6. History of alcoholism or drug abuse within last 2 years.
  7. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days (or 5 half-lives, whichever is longer) prior to the cytisine dose, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.
  8. Participated in any investigational drug clinical trial within the previous 3 months or a marketed drug trial within the previous 30 days prior to randomization on Day 1 of Period 1.
  9. Donation of 450 mL or more blood or had history of significant blood loss due to any reason or had plasmapheresis within 3 months before the cytisine dose.
  10. Any inability or difficulty in fasting.
  11. Inability to communicate well with Investigators (i.e., language problem, poor mental development or impaired cerebral function).
  12. Any other condition that the Principal Investigator considers making the subject unsuitable for this study.

To be Re-Confirmed Prior to Dosing:

  1. Development of any exclusion criteria since screening.
  2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements since screening, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.
  3. Participation in a clinical study since the screening visit.
  4. Donation of 450 mL or more blood since the screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03509948


Locations
Layout table for location information
United Kingdom
Simbec Research Ltd
Cardiff, United Kingdom, CF11 9AB
Sponsors and Collaborators
Achieve Life Sciences
Investigators
Layout table for investigator information
Principal Investigator: Ezanul Abd Wahab, MD Simbec Research Ltd (Simbec)
  Study Documents (Full-Text)

Documents provided by Achieve Life Sciences:
Study Protocol  [PDF] April 3, 2018
Statistical Analysis Plan  [PDF] July 10, 2018


Layout table for additonal information
Responsible Party: Achieve Life Sciences
ClinicalTrials.gov Identifier: NCT03509948     History of Changes
Other Study ID Numbers: ACH-CYT-07
First Posted: April 27, 2018    Key Record Dates
Results First Posted: September 12, 2019
Last Update Posted: September 24, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No